A new paper entitled 'Enveloped Virus-Like Particle Expression of Human Cytomegalovirus Glycoprotein B Antigen Induces Antibodies with Potent and Broad Neutralizing Activity' was published this week in Clinical and Vaccine Immunology. Marc Kirchmeier, author of the paper and VBI's Vice President of Research, discusses how eVLPs can be used to develop a potentially efficacious CMV vaccine.